Medication Guide App

Syrian Rue

Scientific Name(s): Peganum harmala L. Family: Zygophyllaceae (Creosote-bush family)

Common Name(s): African rue , Syrian rue , wild rue , harmal shrub , harmel, isband , ozallalk , steppenraute

Uses

In several countries the plant has been traditionally used as an hallucinogen in ceremonies, and has found its way into modern day recreational use. Although in vitro and animal experiments suggest a role as an antimicrobial, vasorelaxant, antidepressant, analgesic, or cytotoxic agent, clinical studies are lacking to support any therapeutic application.

Dosing

Clinical applications are lacking to provide therapeutic dosages. Consumption of decoctions made from 100 to 150 g of seeds has resulted in toxic effects.

Contraindications

Harmala alkaloids (specifically harmine and harmaline) are reversible monoamine oxidase inhibitors (MAOI), thus concomitant use with MAOI medicines and tyramine-containing foods is not advised.

Pregnancy/Lactation

Documented adverse reactions. Avoid use.

Interactions

None well documented.

Adverse Reactions

Case reports of toxicity include nausea and vomiting, visual and auditory hallucinations, confusion, agitation, locomotor ataxia, tremors and convulsions, and life-threatening respiratory depression and coma. Severe gastrointestinal distress, vomiting blood, gastric ulceration, and convulsions have also been reported, as well as bradycardia and low blood pressure. Symptoms are generally of short duration (a few hours) and supportive therapy is recommended.

Toxicology

Information is limited. Elevated renal and liver function tests have been reported.

Botany

Peganum harmala L. is native to Central Asia and the Mediterranean coasts of Europe, Africa, and the Middle East. In the 1920s, the plant was imported into the United States where it is now considered a noxious weed. The plant's bitter taste allows it to thrive as it is avoided by grazing animals.

The plant is a highly branched perennial shrub that grows from 30 to 60 cm tall. It has narrow leaves arranged alternately on fleshy, bright green stiff stems. The flowers are solitary and are small, white (or pale yellow), and 5-petaled. The fruit capsule is about 6 to 10 mm across, and is green when unripe, turning orange-brown when mature. The capsule contains small black-brown triangular seeds. 1 , 2 , 3

History

The plant was known to Dioscorides (ca. 40 to 90 AD), Galen (ca. 129 to 217 AD), and Avicenna (ca. 980 to 1037 AD) as a psychoactive drug, and the ancient Greeks used powdered seeds to treat recurring fevers and for tapeworm. In Turkey, the dried capsules have been used as a talisman against “evil-eye,” and smoke from burning the dried seeds have been used to treat mental illnesses. In Iran, Iraq, Tajikistan, Afghanistan, Pakistan, and India, the plant has been used as an hallucinogen in ceremonies, and has found its way into modern-day recreational use. It has reportedly been used as an abortifacient. In the Middle East, red dye produced from the seeds has been used for carpets. 2 , 3 , 4

Chemistry

All plant parts are used, although the roots and seeds contain more of the active alkaloids than the stems and leaves. The beta-carboline alkaloids are the most studied and the most pharmacologically active constituents. They include harmine, isoharmine, and harmaline, which are reversible inhibitors of monoamine oxidase A, harmalol, harman, harmalidine, ruine, and tetrahydroharmine. Also present are the quinazolidine alkaloids vasicine (peganine), vasicinone, vascinol, peganol, peganidine, and deoxypeganine. Flavonoids and steroidal compounds have also been described, as well as fatty acids, amino acids, carbohydrates, lipids, protein, and minerals. High-performance liquid chromatography, thin-layer chromatography, gas-liquid chromatography, nuclear magnetic resonance, and ultraviolet methods for the analysis of the various chemical constituents have been described. 2 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 11

Uses and Pharmacology

Antimicrobial activity

In vitro studies have found extracts of P. harmala seeds to have modest activity against several bacteria including Staphylococcus aureus , Salmonella spp., Proteus vulgaris , and Bacillus subtilis , as well as against HIV, fungal strains including Candida albicans , and protozoans and insect larvae. 2 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19

Animal data

In vivo studies in poultry showed efficacy against relevant bacterial and protozoa. 15 , 20 In sheep and cattle intramuscular extracts of P. harmala seeds have been effective in managing infections with the tick-borne parasite Theileria hirci . 21 , 22 Peganine administered orally to hamsters has shown activity against Leishmania . 17 , 23

Clinical data

Research reveals no clinical data regarding the use of Syrian rue for antimicrobial use in humans.

Cardiovascular effects

In vitro studies have largely focused on the vasorelaxant effects of the beta-carboline alkaloids on isolated rat aorta. Activity on endothelial and vascular smooth muscle tissue has been shown and is suggested to be related to calcium channel activity, inhibition of phosphodiesterase, and free radical scavenging. 24 , 25 , 26 Similarly, in vitro vasorelaxant activity has been demonstrated for the quinazolidine alkaloid vasicinone. 18 Antiplatelet activity has been shown in vitro via selective inhibition of aggregation, with no cytotoxic effect on platelet cells. 27

Animal data

Dose-dependent transient hypotension and longer-lasting bradycardia was demonstrated in rodents given harman. 24

Clinical data

There are no clinical data regarding the use of Syrian rue for cardiovascular use. However, reported adverse events include bradycardia and hypotension. 28

CNS effects

Activity of alkaloids extracted from the seeds of P. harmala has been shown to exert acetylcholinesterase and MAO inhibitory activity 2 , 5 , 29 as well as effects on dopamine, 5-hydroxytryptophan, nicotinic, opioid, and muscarinic receptors in rodent and in vitro studies. 30 , 31 , 32 , 33 Beta carbolines have been found in the brain tissue of patients with Parkinson disease and are thought to have a role in the pathophysiology of CNS diseases. 31 , 32

Animal data

Limited studies have been conducted. Decreased nociception has been demonstrated in mice and rats. 33 , 34 Harmane produced an amnesia-like state in mice with no effect on anxiety or locomotor behavior. 31 , 32 Total alkaloid seed extract, as well as isolated harmaline and harmine, produced a centrally mediated hypothermic effect in rats. 30 In alcohol-preferring rats, desoxypeganine produced a dose-dependent reduction in ethanol preference and intake without affecting food or fluid intake. 35

Clinical data

There are no clinical data on the use of Syrian rue for use in treating CNS ailments, although such applications have been proposed. The mechanisms elucidated in animal studies provide the basis for the traditional use of P. harmala as an antidepressant and for its recreational use. 5

Cytotoxic activity

In vitro studies of seed extracts, isolated alkaloids, flavonoids, and sterols have shown cytotoxicity against several human cancer cell lines. 3 , 16 , 36 Inhibition of topoisomerases and interference with DNA and RNA replication have been shown. 37 , 38 , 39 Interference with dioxin-medicated induction of carcinogen-activating enzymes, transcription factors, and cytokines, as well as apoptosis and antiangiogenic activity, have been demonstrated in vitro. 16 , 40 , 41 , 42 , 43

Animal data

Antiangiogenic activity (decreased capillary formation) by harmine was demonstrated in mice in one experiment. A protective effect was found for a P. harmala extract against thiourea-induced cancer in rats. Reduced levels of thyroid and neuroendocrine cancer markers were found, as well as a protective effect for hepatotoxicity caused by thiourea. 44

Clinical data

There are no clinical data regarding the use of Syrian rue for use in cancer.

Hypoglycemic effect

In vitro studies failed to demonstrate increased insulin secreting activity from INS-1 cells exposed to extracts of the hulls of the seeds of P. harmala in a screening experiment. 45

Animal data

The ethanol extract of P. harmala seeds has been reported to exhibit hypoglycemic activity in mice. The same researchers isolated 4-hydroxypipecolic acid and demonstrated decreased fasting blood glucose levels and increased insulin sensitivity in rats fed the extract for 10 days. Decreased cholesterol and increased high-density lipoprotein were also reported. 46

Clinical data

There are no clinical data regarding the use of Syrian rue for use in diabetes or metabolic syndrome.

Other effects
Immune system effects

In vitro studies have shown some inhibitory activity by extracts of the seeds of P. harmala against neutrophils, mononuclear cells, and transcription factor NF-kappaB. However, activity was less than that of other plants studied. 47 , 48

Dosage

Effects may vary. 49 Small doses of seeds (25 to 50 mg) are mildly stimulating and may cause agitation or act as a depressant. 49 Larger doses (300 to 750 mg) have hallucinogenic effects. 49 Consumption of decoctions made from 100 to 150 g of seeds have resulted in toxic effects. 2 , 49 Harmaline and harmine alkaloids are metabolized in the liver and other extrahepatic tissues to the less potent metabolites harmalol and harmol. 5

Pregnancy/Lactation

Documented adverse reactions. Avoid use. Harmala has been used traditionally as an emmenagogue and abortifacient. 2 Reductions in reproduction rates in laboratory rats fed methanol extracts of the plant have been demonstrated. 50

Interactions

Case reports of interactions are lacking. In vitro studies have demonstrated effects of P. harmala beta-carboline alkaloids on cytochrome P450 enzymes, providing a potential basis for interactions with drugs dependent on this pathway. 51 Because harmala alkaloids (specifically harmine and harmaline) are reversible MAOIs, the use of Peganum products in combination with MAOIs and tyramine-containing foods is contraindicated. 2 , 3 , 49 , 52 Tetrahydroharmine inhibits serotonin deamination and may cause serotonin syndrome, although case reports are lacking. 28 , 49

Adverse Reactions

P. harmala is considered a drug of potential abuse due to the sedative and hallucinogenic properties attributed to its effects as an MAOI, as well as to its ability to prevent the deactivation of the recreational hallucinogenic N,N-dimethyltriptamine (DMT) by MAO. Even though combined intake of DMT and Syrian rue is advocated on some internet sites, such use has resulted in MAO-related toxicity, but there are no reports of deaths to date. 5 , 52 , 53

Toxicology

Histological studies in rats have shown liver degeneration and spongiform changes in the CNS. Elevated renal and liver function tests were reported in a case of intoxication from tea made from P. harmala seeds. Oral doses at 0.15% of an animal's body weight are estimated to be lethal. 49 Chickens fed extracts of the seed of P. harmala for 6 weeks showed increases in liver weight, as well as decreased serum alkaline phosphatase, protein, albumin, and globulin. 20 Reductions in reproduction rates in laboratory rats fed methanol extracts of the plant have been demonstrated. 50

Case reports of toxicity include symptoms of nausea and vomiting, visual and auditory hallucinations, confusion, agitation, locomotor ataxia, tremors, and convulsions, and in one report, life-threatening respiratory depression and coma. Severe GI distress, vomiting blood, gastric ulceration, and convulsions have also been reported following consumption of a decoction made from 150 g seeds. Cardiovascular effects including bradycardia and low blood pressure were also reported in one case report of toxicity. Symptoms generally last a few hours, and supportive therapy is recommended. 2 , 28 , 49

Bibliography

1. Peganum harmala L. USDA, NRCS. 2012. The PLANTS Database ( http://plants.usda.gov , 8 March 2012). National Plant Data Team, Greensboro, NC 27401–4901 USA. Accessed March 8, 2012.
2. Marwat SK, ur Rehman F. Medicinal and pharmacological potential of harmala ( Peganum harmala L.) seeds. In: Preedy VR, Watson RR, Patel VB, eds. Nuts and Seeds in Health and Disease Prevention . London, England: Academic Press; 2011: 585-599.
3. Dube A, Misra P, Khaliq T, Tiwari S, Kumar N, Narender T. Therapeutic potential of harmala ( Peganum harmala L.) seeds with an array of pharmacological activities. In: Preedy VR, Watson RR, Patel VB, eds, Nuts and Seeds in Health and Disease Prevention . London, England: Academic Press; 2011: 585–599.
4. Duke JA. Handbook of Medicinal Herbs , 2nd ed. Boca Raton, FL: CRC Press; 2003.
5. Herraiz T, González D, Ancín-Azpilicueta C, Arán VJ, Guillén H. beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem Toxicol . 2010;48(3):839-845.
6. Pulpati H, Biradar YS, Rajani M. High-performance thin-layer chromatography densitometric method for the quantification of harmine, harmaline, vasicine, and vasicinone in Peganum harmala . J AOAC Int . 2008;91(5):1179-1185.
7. Kartal M, Altun ML, Kurucu S. HPLC method for the analysis of harmol, harmalol, harmine and harmaline in the seeds of Peganum harmala L. J Pharm Biomed Anal . 2003;31(2):263-269.
8. Ayoub MT, L.J. Rashan. Isoharmine, a β-carboline alkaloid from Peganum harmala seeds. Phytochemistry . 1991;20(3):1046-1047.
9. Ayoub MT, Rashan LJ, Khazraji AT, Adaay MT. An oxamide from Peganum harmala seeds. Phytochemistry . 1989;28(7):2000-2001.
10. Khan AM, Abbas G, Qureshi RA, Khan U, Ghufran MA, Stoekli-Evans H. 3-Hydr-oxy-1,2,3,9-tetra-hydro-pyrrolo[2,1-b]quinazolin-4-ium chloride dihydrate: (+)-vasicinol hydro-chloride dihydrate from Peganum harmala L. Acta Crystallogr Sect E Struct Rep Online . 2009;65(pt 3):o474-o475.
11. Sharaf M, el-Ansari MA, Matlin SA, Saleh NA. Four flavonoid glycosides from Peganum harmala . Phytochemistry . 1997;44(3):533-536.
12. Ali NH, Faizi S, Kazmi SU. Antibacterial activity in spices and local medicinal plants against clinical isolates of Karachi, Pakistan. Pharm Biol . 2011;49(8):833-839.
13. Hashem M. Antifungal properties of crude extracts of five Egyptian medicinal plants against dermatophytes and emerging fungi. Mycopathologia . 2011;172(1):37-46.
14. Nenaah G. Antibacterial and antifungal activities of (beta)-carboline alkaloids of Peganum harmala (L) seeds and their combination effects. Fitoterapia . 2010;81(7):779-782.
15. Arshad N, Zitterl-Eglseer K, Hasnain S, Hess M. Effect of Peganum harmala or its beta-carboline alkaloids on certain antibiotic resistant strains of bacteria and protozoa from poultry. Phytother Res . 2008;22(11):1533-1538.
16. Zeng Y, Zhang Y, Weng Q, Hu M, Zhong G. Cytotoxic and insecticidal activities of derivatives of harmine, a natural insecticidal component isolated from Peganum harmala . Molecules . 2010;15(11):7775-7791.
17. Khaliq T, Misra P, Gupta S, et al. Peganine hydrochloride dihydrate an orally active antileishmanial agent. Bioorg Med Chem Lett . 2009;19(9):2585-2586.
18. Astulla A, Zaima K, Matsuno Y, et al. Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. J Nat Med . 2008;62(4):470-472.
19. Rehman JU, Wang XG, Johnson MW, et al. Effects of Peganum harmala (Zygophyllaceae) seed extract on the olive fruit fly (Diptera: Tephritidae) and its larval parasitoid Psyttalia concolor (Hymenoptera: Braconidae). J Econ Entomol . 2009;102(6):2233-2240.
20. Arshad N, Neubauer C, Hasnain S, Hess M. Peganum harmala can minimize Escherichia coli infection in poultry, but long-term feeding may induce side effects. Poult Sci . 2008;87(2):240-249.
21. Derakhshanfar A, Mirzaei M. Effect of Peganum harmala ( wild rue ) extract on experimental ovine malignant theileriosis: pathological and parasitological findings. Onderstepoort J Vet Res . 2008;75(1):67-72.
22. Mirzaei M. Treatment of natural tropical theileriosis with the extract of the plant Peganum harmala . Korean J Parasitol . 2007;45(4):267-271.
23. Misra P, Khaliq T, Dixit A, et al. Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother . 2008;62(5):998-1002.
24. Shi CC, Chen SY, Wang GJ, Liao JF, Chen CF. Vasorelaxant effect of harman. Eur J Pharmacol . 2000;390(3):319-325.
25. Shi CC, Liao JF, Chen CF. Comparative study on the vasorelaxant effects of three harmala alkaloids in vitro. Jpn J Pharmacol . 2001;85(3):299-305.
26. Berrougui H, Mart ín-Cordero C, Khalil A, et al. Vasorelaxant effects of harmine and harmaline extracted from Peganum harmala L. seeds in isolated rat aorta. Pharmacol Res . 2006;54(2):150-157.
27. Im JH, Jin YR, Lee JJ, et al. Antiplatelet activity of beta-carboline alkaloids from Perganum harmala : a possible mechanism through inhibiting PLCgamma2 phosphorylation. Vascul Pharmacol . 2009;50(5-6):147-152.
28. Frison G, Favretto D, Zancanaro F, Fazzin G, Ferrara SD. A case of beta-carboline alkaloid intoxication following ingestion of Peganum harmala seed extract. Forensic Sci Int . 2008;179(2-3):e37-e43.
29. Adhami HR, Farsam H, Krenn L. Screening of medicinal plants from Iranian traditional medicine for acetylcholinesterase inhibition. Phytother Res . 2011;25(8):1148-1152.
30. Abdel-Fattah AF, Matsumoto K, Gammaz HA, Watanabe H. Hypothermic effect of harmala alkaloid in rats: involvement of serotonergic mechanism. Pharmacol Biochem Behav . 1995;52(2):421-426.
31. Nasehi M, Sharifi S, Zarrindast MR. Involvement of the cholinergic system of CA1 on harmane-induced amnesia in the step-down passive avoidance test. J Psychopharmacol . 2011 Sep 29. [Epub ahead of print].
32. Nasehi M, Piri M, Nouri M, Farzin D, Nayer-Nouri T, Zarrindast MR. Involvement of dopamine D1/D2 receptors on harmane-induced amnesia in the step-down passive avoidance test. Eur J Pharmacol . 2010;634(1-3):77-83.
33. Farouk L, Laroubi A, Aboufatima R, Benharref A, Chait A. Evaluation of the analgesic effect of alkaloid extract of Peganum harmala L.: possible mechanisms involved. J Ethnopharmacol . 2008;115(3):449-454.
34. Monsef HR, Ghobadi A, Iranshahi M, Abdollahi M. Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test. J Pharm Pharm Sci . 2004;7(1):65-69.
35. Doetkotte R, Opitz K, Kiianmaa K, Winterhoff H. Reduction of voluntary ethanol consumption in alcohol-preferring Alko alcohol (AA) rats by desoxypeganine and galanthamine. Eur J Pharmacol . 2005;522(1-3):72-77.
36. Li Y, Liang F, Jiang W, et al. DH334, a beta-carboline anti-cancer drug, inhibits the CDK activity of budding yeast. Cancer Biol Ther . 2007;6(8):1193-1199.
37. Nafisi S, Malekabady ZM, Khalilzadeh MA. Interaction of β-carboline alkaloids with RNA. DNA Cell Biol . 2010;29(12):753-761.
38. Nafisi S, Bonsaii M, Maali P, Khalilzadeh MA, Manouchehri F. Beta-carboline alkaloids bind DNA. J Photochem Photobiol B . 2010;100(2):84-91.
39. Sobhani AM, Ebrahimi SA, Mahmoudian M. An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids. J Pharm Pharm Sci . 2002;5(1):19-23.
40. Hamsa TP, Kuttan G. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro. Eur J Pharmacol . 2010;649(1-3):64-73.
41. El Gendy MA, Somayaji V, El-Kadi AO. Peganum harmala L. is a candidate herbal plant for preventing dioxin mediated effects. Planta Med . 2010;76(7):671-677.
42. Zaker F, Oody A, Arjmand A. A study on the antitumoral and differentiation effects of peganum harmala derivatives in combination with ATRA on leukaemic cells. Arch Pharm Res . 2007;30(7):844-849.
43. Lamchouri F, Settaf A, Cherrah Y, et al. In vitro cell-toxicity of Peganum harmala alkaloids on cancerous cell-lines. Fitoterapia . 2000;71(1):50-54.
44. Hamden K, Masmoudi H, Ellouz F, ElFeki A, Carreau S. Protective effects of Peganum harmala extracts on thiourea-induced diseases in adult male rat. J Environ Biol . 2008;29(1):73-77.
45. Hussain Z, Waheed A, Qureshi RA, et al. The effect of medicinal plants of Islamabad and Murree region of Pakistan on insulin secretion from INS-1 cells. Phytother Res . 2004;18(1):73-77.
46. Singh AB, Khaliq T, Chaturvedi JP, Narender T, Srivastava AK. Anti-diabetic and anti-oxidative effects of 4-hydroxypipecolic acid in C57BL/KsJ-db/db mice. Hum Exp Toxicol . 2011 Jun 8. [Epub ahead of print].
47. Koko WS, Mesaik MA, Yousaf S, Galal M, Choudhary MI. In vitro immunomodulating properties of selected Sudanese medicinal plants. J Ethnopharmacol . 2008;118(1):26-34.
48. Bremner P, Rivera D, Calzado MA, et al. Assessing medicinal plants from South-Eastern Spain for potential anti-inflammatory effects targeting nuclear factor-Kappa B and other pro-inflammatory mediators. J Ethnopharmacol . 2009;124(2):295-305.
49. Yuruktumen A, Karaduman S, Bengi F, Fowler J. Syrian rue tea: a recipe for disaster. Clin Toxicol (Phila) . 2008;46(8):749-752.
50. Shapira Z, Terkel J, Egozi Y, Nyska A, Friedman J. Abortifacient potential for the epigeal parts of Peganum harmala . J Ethnopharmacol . 1989;27(3):319-325.
51. Zhao T, He YQ, Wang J, Ding KM, Wang CH, Wang ZT. Inhibition of human cytochrome P450 enzymes 3A4 and 2D6 by β-carboline alkaloids, harmine derivatives. Phytother Res . 2011;25(11):1671-1677.
52. Haroz R, Greenberg MI. Emerging drugs of abuse. Med Clin North Am . 2005;89(6):1259-1276.
53. Halpern JH, Sewell RA. Hallucinogenic botanicals of America: A growing need for focused drug education and research. Life Sci . 2005;78(5):519-526.

Copyright © 2009 Wolters Kluwer Health

Hide
(web1)